<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35259014</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Poly-dipeptides produced from <i>C9orf72</i> hexanucleotide repeats cause selective motor neuron hyperexcitability in ALS.</ArticleTitle><Pagination><StartPage>e2113813119</StartPage><MedlinePgn>e2113813119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2113813119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2113813119</ELocationID><Abstract><AbstractText>SignificanceThe GGGGCC hexanucleotide repeat expansion in the chromosome 9 open reading frame 72 (<i>C9orf72</i>) gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS). Despite myriad studies on the toxic effects of poly-dipeptides produced from the <i>C9orf72</i> repeats, the mechanisms underlying the selective hyperexcitability of motor cortex that characterizes the early stages of <i>C9orf72</i> ALS patients remain elusive. Here, we show that the proline-arginine poly-dipeptides cause hyperexcitability in cortical motor neurons by increasing persistent sodium currents conducted by the Nav1.2/&#x3b2;4 sodium channel complex, which is highly expressed in the motor cortex. These findings provide the basis for understanding how the <i>C9orf72</i> mutation causes motor neuron hyperactivation that can lead to the motor neuron death in <i>C9orf72</i> ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Yunhee</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8652-2309</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jiwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seul-Yi</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Physiology, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Ilmin</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0957-1702</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hana</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9394-8671</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019054" MajorTopicYN="N">Evoked Potentials, Motor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006948" MajorTopicYN="N">Hyperkinesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72 ALS</Keyword><Keyword MajorTopicYN="N">PR poly-dipeptides</Keyword><Keyword MajorTopicYN="N">hyperexcitability</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">sodium channels</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>17</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35259014</ArticleId><ArticleId IdType="pmc">PMC8931230</ArticleId><ArticleId IdType="doi">10.1073/pnas.2113813119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M., et al. , Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E., et al. ; ITALSGEN Consortium, A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X. R., Gitler A. D., ALS genetics: Gains, losses, and implications for future therapies. Neuron 108, 822&#x2013;842 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T. F., Belzil V. V., Zhang Y. J., Petrucelli L., Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 127, 359&#x2013;376 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002260</ArticleId><ArticleId IdType="pubmed">24394885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., et al. , Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., et al. , C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A. M., C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 14, 544&#x2013;558 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., et al. , Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A. 110, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., et al. , The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., et al. , RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P. E., et al. , Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C. J., et al. , RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., et al. , C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845&#x2013;857 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., et al. , Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell 167, 789&#x2013;802.e12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C. L., et al. , Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20, 589&#x2013;602 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9539131</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N., Menon P., &#xd6;zdinler P. H., Kiernan M. C., Vucic S., Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat. Rev. Neurol. 12, 651&#x2013;661 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins E. M., et al. , Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Mol. Neurodegener. 16, 13 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931347</ArticleId><ArticleId IdType="pubmed">33663561</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanz O., et al. , Cortical hyperexcitability in patients with C9ORF72 mutations: Relationship to phenotype. Muscle Nerve 54, 264&#x2013;269 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940214</ArticleId><ArticleId IdType="pubmed">26799151</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj B. T., et al. , C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 9, 347 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunes Z. I., Kan V. W. Y., Ye X., Liebscher S., Exciting complexity: The role of motor circuit elements in ALS pathophysiology. Front. Neurosci. 14, 573 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311855</ArticleId><ArticleId IdType="pubmed">32625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin A. C., et al. , Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat. Commun. 6, 5999 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bean B. P., The action potential in mammalian central neurons. Nat. Rev. Neurosci. 8, 451&#x2013;465 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17514198</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinello K., Giacalone E., Migliore M., Brown D. A., Shah M. M., The subthreshold-active KV7 current regulates neurotransmission by limiting spike-induced Ca2+ influx in hippocampal mossy fiber synaptic terminals. Commun. Biol. 2, 145 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486593</ArticleId><ArticleId IdType="pubmed">31044170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M. C., Adimula A., Birch D., Heckman C. J., Hyperexcitability in synaptic and firing activities of spinal motoneurons in an adult mouse model of amyotrophic lateral sclerosis. Neuroscience 362, 33&#x2013;46 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614896</ArticleId><ArticleId IdType="pubmed">28844763</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W., et al. , mGluR5-dependent modulation of dendritic excitability in CA1 pyramidal neurons mediated by enhancement of persistent Na+ currents. J. Physiol. 596, 4141&#x2013;4156 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117564</ArticleId><ArticleId IdType="pubmed">29870060</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul J. R., et al. , Regulation of persistent sodium currents by glycogen synthase kinase 3 encodes daily rhythms of neuronal excitability. Nat. Commun. 7, 13470 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114562</ArticleId><ArticleId IdType="pubmed">27841351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., et al. , Isoflurane modulates hippocampal cornu ammonis pyramidal neuron excitability by inhibition of both transient and persistent sodium currents in mice. Anesthesiology 131, 94&#x2013;104 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6586485</ArticleId><ArticleId IdType="pubmed">31166240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezmy J., et al. , M-current inhibition rapidly induces a unique CK2-dependent plasticity of the axon initial segment. Proc. Natl. Acad. Sci. U.S.A. 114, E10234 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703290</ArticleId><ArticleId IdType="pubmed">29109270</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablo J. L., Pitt G. S., FGF14 is a regulator of KCNQ2/3 channels. Proc. Natl. Acad. Sci. U.S.A. 114, 154&#x2013;159 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224356</ArticleId><ArticleId IdType="pubmed">27994149</ArticleId></ArticleIdList></Reference><Reference><Citation>Verneuil J., et al. , The M-current works in tandem with the persistent sodium current to set the speed of locomotion. PLoS Biol. 18, e3000738 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688130</ArticleId><ArticleId IdType="pubmed">33186352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Ou S. W., Wang Y. J., Distribution and function of voltage-gated sodium channels in the nervous system. Channels (Austin) 11, 534&#x2013;554 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5786190</ArticleId><ArticleId IdType="pubmed">28922053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull J. M., Isom L. L., Voltage-gated sodium channel &#x3b2; subunits: The power outside the pore in brain development and disease. Neuropharmacology 132, 43&#x2013;57 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856584</ArticleId><ArticleId IdType="pubmed">28927993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., et al. , Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. Nat. Neurosci. 12, 996&#x2013;1002 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19633666</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Malley H. A., Isom L. L., Sodium channel &#x3b2; subunits: Emerging targets in channelopathies. Annu. Rev. Physiol. 77, 481&#x2013;504 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4817109</ArticleId><ArticleId IdType="pubmed">25668026</ArticleId></ArticleIdList></Reference><Reference><Citation>Haustrate A., Hantute-Ghesquier A., Prevarskaya N., Lehen&#x2019;kyi V., Monoclonal antibodies targeting ion channels and their therapeutic potential. Front. Pharmacol. 10, 606 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561378</ArticleId><ArticleId IdType="pubmed">31231216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H., Li M., Antibody therapeutics targeting ion channels: Are we there yet? Acta Pharmacol. Sin. 34, 199&#x2013;204 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011603</ArticleId><ArticleId IdType="pubmed">23381110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., et al. , 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel &#x3b1;2&#x3b4;1 subunit. Cancer Cell 23, 541&#x2013;556 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23597567</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall W. A., Forty years of sodium channels: Structure, function, pharmacology, and epilepsy. Neurochem. Res. 42, 2495&#x2013;2504 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5693772</ArticleId><ArticleId IdType="pubmed">28589518</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassilev P., Scheuer T., Catterall W. A., Inhibition of inactivation of single sodium channels by a site-directed antibody. Proc. Natl. Acad. Sci. U.S.A. 86, 8147&#x2013;8151 (1989).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298232</ArticleId><ArticleId IdType="pubmed">2554301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilchrist J., Das S., Van Petegem F., Bosmans F., Crystallographic insights into sodium-channel modulation by the &#x3b2;4 subunit. Proc. Natl. Acad. Sci. U.S.A. 110, E5016&#x2013;E5024 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870679</ArticleId><ArticleId IdType="pubmed">24297919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., et al. , Neddylation stabilizes Nav1.1 to maintain interneuron excitability and prevent seizures in murine epilepsy models. J. Clin. Invest. 131, e136956 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262483</ArticleId><ArticleId IdType="pubmed">33651714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.-J., et al. , C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 19, 668&#x2013;677 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark R. M., Blizzard C. A., Young K. M., King A. E., Dickson T. C., Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1G93A mouse model of ALS. Sci. Rep. 7, 44461 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5353592</ArticleId><ArticleId IdType="pubmed">28294153</ArticleId></ArticleIdList></Reference><Reference><Citation>Khademullah C. S., et al. , Cortical interneuron-mediated inhibition delays the onset of amyotrophic lateral sclerosis. Brain 143, 800&#x2013;810 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32203578</ArticleId></ArticleIdList></Reference><Reference><Citation>Thielsen K. D., et al. , The Wobbler mouse model of amyotrophic lateral sclerosis (ALS) displays hippocampal hyperexcitability, and reduced number of interneurons, but no presynaptic vesicle release impairments. PLoS One 8, e82767 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859636</ArticleId><ArticleId IdType="pubmed">24349357</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck H., Yaari Y., Plasticity of intrinsic neuronal properties in CNS disorders. Nat. Rev. Neurosci. 9, 357&#x2013;369 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18425090</ArticleId></ArticleIdList></Reference><Reference><Citation>Jover E., Massacrier A., Cau P., Martin M. F., Couraud F., The correlation between Na+ channel subunits and scorpion toxin-binding sites. A study in rat brain synaptosomes and in brain neurons developing in&#xa0;vitro. J. Biol. Chem. 263, 1542&#x2013;1548 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2447092</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee N. S., et al. , The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J. Biol. Chem. 271, 5768&#x2013;5776 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8621444</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Gilchrist J., Bosmans F., Van Petegem F., Binary architecture of the Nav1.2-&#x3b2;2 signaling complex. eLife 5, e10960 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769172</ArticleId><ArticleId IdType="pubmed">26894959</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmas P., Brown D. A., Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat. Rev. Neurosci. 6, 850&#x2013;862 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16261179</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentsch T. J., Neuronal KCNQ potassium channels: Physiology and role in disease. Nat. Rev. Neurosci. 1, 21&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11252765</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D. A., Passmore G. M., Neural KCNQ (Kv7) channels. Br. J. Pharmacol. 156, 1185&#x2013;1195 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697739</ArticleId><ArticleId IdType="pubmed">19298256</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder B. C., Kubisch C., Stein V., Jentsch T. J., Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature 396, 687&#x2013;690 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9872318</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., et al. , GABA-B controls persistent Na+ current and coupled Na+-activated K+ current. eNeuro 4, ENEURO.0114-17.2017 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482115</ArticleId><ArticleId IdType="pubmed">28660246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M. C., et al. , Amyotrophic lateral sclerosis. Lancet 377, 942&#x2013;955 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein L. H., Abrahams S., Changes in cognition and behaviour in amyotrophic lateral sclerosis: Nature of impairment and implications for assessment. Lancet Neurol. 12, 368&#x2013;380 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R. H. Jr., Genetics of amyotrophic lateral sclerosis. Cold Spring Harb. Perspect. Med. 8, a024125 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood H., A hexanucleotide repeat expansion in C9ORF72 links amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Rev. Neurol. 7, 595 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22009283</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzicki D., Liu E., Deng H. X., Siddique T., Martina M., Early impairment of synaptic and intrinsic excitability in mice expressing ALS/dementia-linked mutant UBQLN2. Front. Cell. Neurosci. 10, 216 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028382</ArticleId><ArticleId IdType="pubmed">27703430</ArticleId></ArticleIdList></Reference><Reference><Citation>Storm J. F., Action potential repolarization and a fast after-hyperpolarization in rat hippocampal pyramidal cells. J. Physiol. 385, 733&#x2013;759 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1192370</ArticleId><ArticleId IdType="pubmed">2443676</ArticleId></ArticleIdList></Reference><Reference><Citation>White M. R., et al. , C9orf72 Poly(PR) dipeptide repeats disturb biomolecular phase separation and disrupt nucleolar function. Mol. Cell 74, 713&#x2013;728.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525025</ArticleId><ArticleId IdType="pubmed">30981631</ArticleId></ArticleIdList></Reference><Reference><Citation>McColgan P., Joubert J., Tabrizi S. J., Rees G., The human motor cortex microcircuit: Insights for neurodegenerative disease. Nat. Rev. Neurosci. 21, 401&#x2013;415 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32555340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball H. L., Mascagni P., Chemical synthesis and purification of proteins: A methodology. Int. J. Pept. Protein Res. 48, 31&#x2013;47 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8844261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., et al. , Changes in the excitability of neocortical neurons in a mouse model of amyotrophic lateral sclerosis are not specific to corticospinal neurons and are modulated by advancing disease. J. Neurosci. 37, 9037&#x2013;9053 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5597984</ArticleId><ArticleId IdType="pubmed">28821643</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman D. H., Lossin C., The Nav channel bench series: Plasmid preparation. MethodsX 1, 6&#x2013;11 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4472833</ArticleId><ArticleId IdType="pubmed">26150927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., et al. , Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell 167, 789&#x2013;802.e712 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>